These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 1484319)

  • 1. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
    Mayall FG; Goddard H; Gibbs AR
    J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM; Butcher DN; Corrin B; Nicholson AG
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 immunostaining in differential diagnosis of pleural mesothelial proliferations.
    Esposito V; Baldi A; De Luca A; Claudio PP; Signoriello G; Bolognese A; Centonze P; Giordano GG; Caputi M; Baldi F; Giordano A
    Anticancer Res; 1997; 17(1B):733-6. PubMed ID: 9066611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium.
    Ramael M; Lemmens G; Eerdekens C; Buysse C; Deblier I; Jacobs W; van Marck E
    J Pathol; 1992 Dec; 168(4):371-5. PubMed ID: 1484318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
    Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
    J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens.
    Cagle PT; Brown RW; Lebovitz RM
    Hum Pathol; 1994 May; 25(5):443-8. PubMed ID: 8200637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
    Hasteh F; Lin GY; Weidner N; Michael CW
    Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thoracoscopic anatomy, significance of pathologic findings in thoracoscopic open lung biopsy, and pleural mesothelioma].
    Kawai T; Watanabe M; Takagi K
    Nihon Kyobu Shikkan Gakkai Zasshi; 1994 Dec; 32 Suppl():142-7. PubMed ID: 7602822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions.
    Wu M; Sun Y; Li G; Desman G; Wang B; Gil J; Burstein DE
    Am J Clin Pathol; 2007 Nov; 128(5):783-7. PubMed ID: 17951200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computerized interactive morphometry. A study of malignant mesothelioma and mesothelial hyperplasia in pleural biopsy specimens.
    Marchevsky AM; Gil J; Caccamo D
    Arch Pathol Lab Med; 1985 Dec; 109(12):1102-5. PubMed ID: 3840984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 expression is common in malignant mesothelioma.
    Kafiri G; Thomas DM; Shepherd NA; Krausz T; Lane DP; Hall PA
    Histopathology; 1992 Oct; 21(4):331-4. PubMed ID: 1398535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
    Lagana SM; Taub RN; Borczuk AC
    Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.
    Roberts F; McCall AE; Burnett RA
    J Clin Pathol; 2001 Oct; 54(10):766-70. PubMed ID: 11577123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
    Deniz H; Kibar Y; Güldür ME; Bakir K
    Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
    Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
    Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
    Roberts F; Harper CM; Downie I; Burnett RA
    Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.